Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MM120 in Generalized Anxiety Disorder
NCT05407064Phase 2Completed
- Sponsor
- Definium Therapeutics
- Start
- Aug 2022
- Primary completion
- Oct 2023
- Countries
- 1
01
Overview
A Phase 2 trial of lysergic acid diethylamide D-tartrate in generalized anxiety disorder (GAD), sponsored by Definium Therapeutics. Started Aug 2022; status: completed.
02
Drugs
lysergic acid diethylamide D-tartrate
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT05407064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05407064.